



STATE OF HAWAII
DEPARTMENT OF HEALTH
P. O. Box 3378
Honolulu, HI 96801-3378
doh.testimony@doh.hawaii.gov

Testimony COMMENTING on HB1794 HD1
RELATING TO OPIOIDS

REPRESENTATIVE RYAN I. YAMANE, CHAIR
HOUSE COMMITTEE ON HEALTH, HUMAN SERVICES AND HOMELESSNESS
Hearing Date: 2/15/2022 Room Number: Videoconference

1 **Fiscal Implications:** Undetermined

2 **Department Testimony:** The Department offers the following comments and offers
3 amendments on developing and implementing value-based purchasing (VBP) for patients with
4 opioid use disorders.

5 This measure may be unnecessary because the Department through the Hawaii Opioid Initiative
6 already has a Workgroup on Data-Informed Decision Making and Evaluation who could develop
7 new annual objectives as well as a process to implement VBP.

8 July 1, 2024 is the earliest start date for the Department to “develop and implement standard
9 quality metrics.” Consequently, January 1, 2025 is the earliest start date to “implement value-
10 based purchasing.” A project as complex as this typically takes three years to fully implement.

11 The additional requirement to establish a working group was not in the original bill, and given its
12 one-year existence, requires an additional 1.0 FTE position to implement.

13 The information currently required may already be collected by other government entities.
14 Mandating the Department to collect the same information for VBP implementation will involve
15 significant changes to current legacy data systems within the Department at considerable cost.

16 The measure does not contain any appropriation for the VBP project. The Department requests a
17 revenue stream to carry out the intent of HB 1794 HD1.

18 Thank you for the opportunity to testify on this measure.

1 **Offered Amendments:** The Department proposes two amendments:

2 Page 1, line 5:

3 “(a) By [~~January 1, 2024~~] July 1, 2024, the department of
4 health”

5 Page 1, line 16:

6 “(c) By [~~July 1, 2024~~] January 1, 2025, the department of
7 health shall”

TESTIMONY ON BEHALF OF HAWAII PSYCHIATRIC MEDICAL ASSOCIATION

To: Chair Ryan Yamane, Vice-Chair Adrian Tam
Members of the Committee on Health, Human Services & Homelessness

From: Dr. Marva Lawson, Legislative Committee Co-Chair
Hawaii Psychiatric Medical Association

Time: 9:00 a.m., February 15, 2022

Re: HB 1794, Relating to Opioids

Position: **COMMENT**

On behalf of the Hawaii Psychiatric Medical Association (HPMA) we are writing to comment on HB 1794, relating to opioids. This bill, among other provisions, establishes a working group to determine major shifts in operations and clinical models that substance use disorder treatment providers need to make before adjusting to efforts to incentivize new demands for higher quality care.

While we support the intent we would ask for an amendment that a Medical Doctor Specializing in substance abuse and psychiatry be a member of the working group.

We thank the committee for considering our testimony.